SCHEMBL4097204

SCHEMBL4097204

COc1ccc(-c2cc(N)c(C(N)=O)s2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 8/20 1.00
MAPT P10636 6/20 0.68
KDM4E B2RXH2 4/20 0.68
ALDH1A1 P00352 3/20 0.68
NPC1 O15118 3/20 0.68
RAB9A P51151 3/20 0.68
CASP3 P42574 2/20 0.68
SENP8 Q96LD8 2/20 0.68
SENP7 Q9BQF6 2/20 0.68
SENP6 Q9GZR1 2/20 0.68
MEN1 O00255 1/20 0.68
TP53 P04637 1/20 0.68
HPGD P15428 1/20 0.68
KMT2A Q03164 1/20 0.68
HSD17B10 Q99714 1/20 0.68
CYP1A2 P05177 2/20 0.68
CYP3A4 P08684 2/20 0.68
CYP2C9 P11712 2/20 0.68
CHUK O15111 1/20 0.68
CYP2C19 P33261 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5193028 0.88 IKBKB (0.78) IKBKBMAPTKDM4EALDH1A1NPC1
SCHEMBL4093065 0.87 IKBKB (0.76) IKBKBMAPTKDM4EALDH1A1NPC1
SCHEMBL5195941 0.86 KDM4E (0.76) IKBKBMAPTKDM4EALDH1A1NPC1
SCHEMBL6611685 0.84 IKBKB (0.72) IKBKBMAPTKDM4EALDH1A1NPC1
SCHEMBL7055446 0.84 IKBKB (0.72) IKBKBMAPTKDM4EALDH1A1NPC1
SCHEMBL6612593 0.83 IKBKB (0.76) IKBKBMAPTKDM4EALDH1A1NPC1
SCHEMBL6608113 0.82 IKBKB (0.73) IKBKBMAPTKDM4EALDH1A1NPC1
SCHEMBL10725054 0.81 MAPT (1.00) IKBKBMAPTKDM4EALDH1A1NPC1
SCHEMBL4097325 0.81 IKBKB (1.00) IKBKBMAPTKDM4EALDH1A1NPC1
SCHEMBL4091841 0.81 IKBKB (1.00) IKBKBMAPTKDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166639-B2 NF-κB inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-01-23 US claimed
US-20040192943-A1 Nf-kappab inhibitors SMITHKLINE BEECHAM CORPORATION 2004-09-30 US claimed
CN-113318111-A Application of Nav1.1 agonist in preparation of drugs for treating autism 浙江大学 2021-08-31 CN disclosed
US-20090181962-A1 Substituted thiophene compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2009-07-16 US disclosed
US-7358376-B2 Substituted Thiophene compounds ASTRAZENECA AB (SE) 2008-04-15 US disclosed
EP-1261600-B1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 ASTRAZENECA AB (SE) 2004-05-06 EP disclosed
WO-2003028731-A1 CHK1 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-04-10 WO disclosed
EP-1261600-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 AstraZeneca AB (SE) 2002-12-04 EP disclosed
US-20020107252-A1 Novel Compounds ASTRAZENECA AB (SE) 2002-08-08 US disclosed
WO-2001058890-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 ASTRAZENECA AB (SE) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181962-A1 Substituted thiophene compounds ABCG2, SULT1E1, TPMT IKBKB 3065/4885MAPT 2469/4885KDM4E 652/4885
US-20020107252-A1 Novel Compounds UGT1A1, CYP1B1, CYP1A1 IKBKB 2413/4885MAPT 2580/4885KDM4E 1332/4885
US-20040192943-A1 Nf-kappab inhibitors NFKBIA, IKBKB, IKBKG IKBKB 2/4885MAPT 1500/4885KDM4E 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.